Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step toward advancing its oncology pipeline by executing a term sheet with arm's-length institutional investors for a non-brokered private placement valued at approximately CAD$5 million. The offering, structured as 6,764,070 units at a notional price of CAD$0.7392 per unit, is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals.
Each unit in the offering comprises one common share and one common share purchase warrant. The company's economic interest under the proposed structure will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details to be provided upon closing. The private placement was previously announced and the signing of the term sheet marks a key milestone in the financing process.
The proceeds from the financing are intended to support the development of Onco-Innovations' ONC010 program, which includes manufacturing and preclinical testing activities. Additionally, funds will be allocated to advance the company's SynoGraph platform and for general working capital purposes. This capital injection is crucial for Onco-Innovations as it seeks to progress its research and development efforts in the competitive oncology space.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a focus on oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumors, positioning it to address significant unmet medical needs.
The private placement comes at a time when the company is actively advancing its pipeline. The ONC010 program represents a key asset in Onco's portfolio, and the additional funding will enable the company to move forward with manufacturing and preclinical testing, which are essential steps toward clinical development. The SynoGraph platform, which is also set to benefit from the financing, is another area of focus for the company.
For investors, this announcement signals continued momentum for Onco-Innovations as it secures the necessary capital to execute its strategic plan. The involvement of institutional investors adds credibility to the company's prospects. The terms of the private placement, including the settlement structure, reflect a tailored approach to financing that aligns investor and company interests.
More details on the offering and the company's progress are expected upon closing. Investors can stay informed by visiting the company's newsroom at https://ibn.fm/ONNVF. The full press release is available at https://ibn.fm/y3hsM.
